Check Cap

Check Cap Net Debt / EBITDA

The Net Debt to EBITDA of Check Cap (MBAI) as of Oct 9, 2026 is 0.09. In the previous year, Net Debt to EBITDA was 0.01 — a change of 1,610.12% (higher).

Net Debt / EBITDA

0.09

YoY

1,610.12%

Last updated:

Net Debt to EBITDA of Check Cap is 2025 0.09 . Net Debt to EBITDA of Check Cap was 2024 0.01 . It decreases by 1,610.12% higher compared to the previous year.

The Check Cap Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2021
2.91 USD
Jan 1, 2022
2.08 USD
Jan 1, 2024
0.01 USD
Jan 1, 2025
0.09 USD
The Check Cap Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.09+1,610.12%
0.01-99.76%
2.08-28.70%
2.91—
Access this data via the Eulerpool API

Check Cap Stock analysis

What does Check Cap do? Check Cap Ltd is an international biotech company specializing in the development of non-invasive diagnostic technologies for early detection of colon cancer. The company is headquartered in Israel and was founded in 2004. Check Cap is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Check Cap stock

Net Debt to EBITDA of Check Cap is 0.09 in 2025.

Net Debt to EBITDA of Check Cap changed from 0.01 to 0.09, representing a 1,610.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Check Cap since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Check Cap with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Check Cap

All Key Metrics — Check Cap